Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today

Targeted therapies are becoming more common treatment options for patients with multiple myeloma. Specifically, there have been emerging clinical data on GPRC5D-directed bispecific antibodies for patients with relapsed and refractory disease. In this podcast, 2 experts in the field discuss how they are using GPRC5D-directed therapies in their practice, including treatment planning, patient selection, adverse event management, and how new combination strategies may affect practice.